The Economics of Reproducibility in Preclinical Research

被引：701

作者：

Freedman, Leonard P. ^{[1
]}

Cockburn, Iain M. ^{[2
]}

Simcoe, Timothy S. ^{[2
,3
]}

机构：

[1] Global Biol Stand Inst, Washington, DC USA

[2] Boston Univ, Sch Management, Boston, MA 02215 USA

[3] Council Econ Advisers, Washington, DC USA

来源：

PLOS BIOLOGY | 2015年 / 13卷 / 06期

关键词：

INCREASING VALUE; IMPACT;

D O I：

10.1371/journal.pbio.1002165

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

070307 [化学生物学]; 071010 [生物化学与分子生物学];

摘要：

Low reproducibility rates within life science research undermine cumulative knowledge production and contribute to both delays and costs of therapeutic drug development. An analysis of past studies indicates that the cumulative (total) prevalence of irreproducible preclinical research exceeds 50%, resulting in approximately US$28,000,000,000 (US $28B)/year spent on preclinical research that is not reproducible-in the United States alone. We outline a framework for solutions and a plan for long-term improvements in reproducibility rates that will help to accelerate the discovery of life-saving therapies and cures.

引用

页码：1 / 9

页数：9

共 34 条

[1]

[Anonymous], 38 AAAS

[2]

Two Years Later: Journals Are Not Yet Enforcing the ARRIVE Guidelines on Reporting Standards for Pre-Clinical Animal Studies [J].